Business · 22/08/2012Updated: 10/17/2026 · 1 min read
FDA Withdraws Approval of 27 Ranbaxy-Submitted Abbreviated New Drug Applications
Summary
The US Food and Drug Administration (FDA) has withdrawn the approval of 27 abbreviated new drug applications (ANDAs) submitted by Ranbaxy Laboratories Ltd., following a request from the company itself, due to the fact that the corresponding drug products are no longer marketed.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →